Roxana et al. [5] first analyzed the expression of CCAT2 in normal breast tissue and breast cancer tissue by RT-qPCR and observed that breast cancer patients with high CCAT2 expression could not benefit from cyclophosphamide (CTX) + 5-fluorouracil (5-FU) + methotrexate (CMF) adjuvant chemotherapy, and these patients often had a shorter survival duration. The gene discussed is CCAT2; the disease is breast cancer.